Puma Bio down 33% as more patients forgoing treatment with its cancer drug
Shares of Puma Biotechnology Inc. fell nearly 33% Thursday after the biotech company reported a narrower-than-expected first-quarter loss and sales that beat expectations, but said net product revenue, centered on its one drug commercially available, came in below its own expectations. Puma said it lost $10.1 million, or 26 cents a share, in the quarter, compared with a loss of $24.3 million, or 65 cents a share, in the year-ago period. Adjusted for one-time items, Puma earned $8.1 million, or 20 cents a share... Читать дальше...